Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Marsh McLennan

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

Analyst Ratings for Marsh & McLennan

Analyst Ratings for Marsh & McLennan

Within the last quarter, Marsh & McLennan (NYSE:MMC) has observed the following analyst ratings:

$100 Invested Marsh & McLennan Stock 5 Years Ago Would Be Worth This Much

$100 Invested Marsh & McLennan Stock 5 Years Ago Would Be Worth This Much

Marsh & McLennan (NYSE:MMC) has outperformed the market over the past 5 years by 6.21% on an annualized basis producing an average annual return of 18.7%. Currently, Marsh & McLennan has a market capitalization of $86.60 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Insurance Stocks Moving In Thursday's Intraday Session

According to Benzinga Pro following are the gainers and losers in Insurance industry for today's Intraday session.

Recap: Marsh & McLennan Q1 Earnings

Marsh & McLennan (NYSE:MMC) reported its Q1 earnings results on Thursday, April 21, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Marsh & McLennan's Earnings Outlook

Marsh & McLennan (NYSE:MMC) is set to give its latest quarterly earnings report on Thursday, 2022-04-21. Here's what investors need to know before the announcement. Analysts estimate that Marsh & McLennan will report an earnings per share (EPS) of $2.14.

Organisations

Vertex Pharmaceuticals

B of A Securities

Charter Communications

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play